AVR

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change -0.11
Percentage change -3.46	%

Held by: IWM IWO VTWO IWC RSSL VTWV VTWG UWM URTY ITWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.27	Insider Own	0.21%	Shs Outstand	36.06M	Perf Week	-11.78%
Market Cap	110.71M	Forward P/E	-	EPS next Y	-2.00	Insider Trans	0.00%	Shs Float	35.99M	Perf Month	-40.04%
Enterprise Value	63.63M	PEG	-	EPS next Q	-0.55	Inst Own	60.61%	Short Float	2.64%	Perf Quarter	4.24%
Income	-81.81M	P/S	44.46	EPS this Y	40.22%	Inst Trans	36.86%	Short Ratio	3.95	Perf Half Y	-45.47%
Sales	2.49M	P/B	2.56	EPS next Y	8.86%	ROA	-216.87%	Short Interest	0.95M	Perf YTD	-44.98%
Book/sh	1.20	P/C	2.26	EPS next 5Y	21.72%	ROE	-341.85%	52W High	8.79 -65.07%	Perf Year	-
Cash/sh	1.36	P/FCF	-	EPS past 3/5Y	-57.99% -	ROIC	-186.67%	52W Low	2.34 31.20%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.10% -	Gross Margin	-1.64%	Volatility	8.51% 9.94%	Perf 5Y	-
Dividend TTM	-	EV/Sales	25.55	EPS Y/Y TTM	-57.85%	Oper. Margin	-3304.45%	ATR (14)	0.39	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.65	Sales Y/Y TTM	2.58%	Profit Margin	-3281.87%	RSI (14)	32.86	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.67	EPS Q/Q	-33.46%	SMA20	-18.18%	Beta	-	Target Price	17.50
Payout	-	Debt/Eq	0.05	Sales Q/Q	-27.45%	SMA50	-25.85%	Rel Volume	0.75	Prev Close	3.18
Employees	136	LT Debt/Eq	0.01	Earnings	May 28	SMA200	-40.36%	Avg Volume	240.33K	Price	3.07
IPO	Dec 13, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	-24.16% 19.13%	Trades		Volume	183,420	Change	-3.46%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-25	Initiated	Lake Street	Buy	$20
Jan-07-25	Initiated	TD Cowen	Buy	$15
Jan-07-25	Initiated	Cantor Fitzgerald	Overweight	$9
Jan-07-25	Initiated	Barclays	Overweight	$22

Jun-09-25 10:52PM	Anteris Appoints David Roberts and Gregory Moss to its Board of Directors (GlobeNewswire) +13.29%
May-13-25 05:45PM	Anteris Announces Results for the First Quarter of 2025 (GlobeNewswire) -9.89%
Mar-31-25 07:15AM	Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR THV (GlobeNewswire)
Mar-21-25 07:30AM	Anteris Reports One-Year Patient Outcomes for DurAVR THV (GlobeNewswire) -10.16%
Mar-12-25 08:33PM	Anteris Reports 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -6.18%
08:00AM	Loading…
Feb-28-25 08:00AM	Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays (GlobeNewswire)
Dec-16-24 07:49PM	Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering (Business Wire)
Dec-12-24 10:34PM	Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering (Business Wire)

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Seaberg John D	Director	Mar 06 '25	Option Exercise	7.13	40,000	285,200	40,000	Mar 20 07:43 PM
Paterson Wayne	Chief Executive Officer	Mar 05 '25	Option Exercise	7.13	233,000	1,661,290	233,000	Mar 20 07:40 PM
Denaro Stephen	Director	Mar 11 '25	Option Exercise	7.13	16,500	117,645	23,722	Mar 20 07:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Anteris Technologies Global Corp

Upgrade your FINVIZ experience